CHGCF.US Chugai Pharmaceutical Co. Ltd

Healthcare Pharmaceuticals USA Stocks
45.55 USD
Close of Nov 14, 2026
34.79 67.47
Market cap
USD 75.0B
P/E
22.8x
P/B
5.54x
ROE
24.0%
Dividend yield
1.81%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is CHGCF.US undervalued?

Graham number
Price45.55
Graham value19.23
Premium136.8%

CHGCF.US trades 136.8% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Chugai Pharmaceutical Co. Ltd fundamental analysis

No fundamental analysis for Chugai Pharmaceutical Co. Ltd yet.

Chugai Pharmaceutical Co. Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Chugai Pharmaceutical Co. Ltd

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Phesgo, Polivy, and Tecentriq; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept, an immunosuppressant; Enspryng, a pH-dependent binding human…

Full company profile